Catalyst Dossier · compiled by CeliA 🧫

MapLight Therapeutics, Inc. (MPLT)

Pharmaceutical Preparations · market cap $1.2B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

MapLight Therapeutics (MPLT) is a clinical-stage pharmaceutical company with 114 employees and a ~$1.57B market cap, focused on CNS disorders. Its lead asset ML-007C-MA is in Phase 2 for Psychosis Associated with Alzheimer's Disease, with additional Phase 2 programs in Autism Spectrum Disorder (ML-004) and Schizophrenia (ML-007C-MA BID). Three Phase 2 readouts are expected between Q4 2026 and Q1 2027, making the next 6–9 months a concentrated catalyst window.

The catalyst path

2026-08-13Earningsimp 5/10
2026-10-15 (est.)Phase 2 · ML-004 (IR)/(ER) tabletimp 7/10
2027-01-15 (est.)Phase 2 · ML-007C-MA BIDimp 7/10
2027-02-15 (est.)Phase 2 · ML-007C-MAimp 7/10

Pipeline

Asset	Phase	Indication
ML-007C-MA	Phase 2	Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet	Phase 2	Autism Spectrum Disorder
ML-007C-MA BID	Phase 2	Schizophrenia

Price & technical context

3-month

+78.1%

6-month

+106.9%

12-month

—

52-wk range

$12.81–$37.09

vs 50-day MA

+24.3%

vs 200-day MA

—

Realized vol

82.7%

Max drawdown

-30.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MPLT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.